Genomics In Drug Discovery And Development
Download Genomics In Drug Discovery And Development full books in PDF, epub, and Kindle. Read online free Genomics In Drug Discovery And Development ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Dimitri Semizarov |
| Publisher | : John Wiley & Sons |
| Total Pages | : 496 |
| Release | : 2008-11-03 |
| Genre | : Medical |
| ISBN | : 0470409762 |
Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists.
| Author | : Federico Innocenti |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 379 |
| Release | : 2008-10-30 |
| Genre | : Medical |
| ISBN | : 1603270884 |
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. As a consequence of the intrinsic chromosomal and genetic instability of the tumor genome, it is generally believed that tailoring of chemotherapy in cancer - tients might be achieved by molecular analysis of patient tumor DNA. In addition, to reduce the toxicity risk of patients, the tumor DNA information should be in- grated with the available data on polymorphic drug-metabolizing enzyme and tra- porter genes mediating the exposure of patients to active drugs and/or their active metabolites. The chapters of this book clearly show how DNA information from both the host (germline) and the tumor should be taken into account for rational selection of drug therapies in cancer patients, an aspect that received little attention, despite its importance. The availability of new molecular approaches to the selection of drug therapy is an emerging need, because the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many treated patients do not experience signi?cant bene?ts from the treatment, while they often experience moderate to severe toxicities. In addition, the development and clinical use of novel molecularly targeted agents (alone or in combination with classical cytotoxic therapy) requires the und- standing of the molecular features of the tumors and the identi?cation of tumor markers of response.
| Author | : Qing Yan |
| Publisher | : Humana Press |
| Total Pages | : 0 |
| Release | : 2014-08-23 |
| Genre | : Medical |
| ISBN | : 9781493909551 |
Covering topics from individual molecules to systemic diseases, from basic concepts to advanced technologies, Pharmacogenomics in Drug Discovery and Development , Second Edition provides a practical, state-of-the-art and integrative view of the application of pharmacogenomics in drug discovery and development. A wide range of theoretical and experimental approaches are introduced to meet the problem-solving objectives for understanding the complexity in health and diseases, from laboratory tests to computational analysis. The development of pharmacogenomics represents the evolution of biomedicine from treating the disease itself to treating the malfunction of an individual person, the “root” of diseases. With the change of focus from disease-centered to human-centric medicine, pharmacogenomics brings hope for the transformation from simple disease treatment to accurate prediction and effective prevention. Written in the successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and easily accessible, Pharmacogenomics in Drug Discovery and Development, Second Edition seeks to serve both professionals and novices with comprehensive resources and a holistic view for the translation of pharmacogenomics into better preventive and personalized medical care.
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 89 |
| Release | : 2012-11-21 |
| Genre | : Medical |
| ISBN | : 0309260272 |
The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-Based Therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead.
| Author | : Kishore R. Sakharkar |
| Publisher | : |
| Total Pages | : 451 |
| Release | : 2015 |
| Genre | : Drug development |
| ISBN | : 9788793102859 |
| Author | : Brian W. Metcalf |
| Publisher | : Elsevier |
| Total Pages | : 293 |
| Release | : 2011-04-28 |
| Genre | : Medical |
| ISBN | : 0080465978 |
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 145 |
| Release | : 2017-10-17 |
| Genre | : Medical |
| ISBN | : 0309462665 |
Those involved in the drug development process face challenges of efficiency and overall sustainability due in part to high research costs, lengthy development timelines, and late-stage drug failures. Novel clinical trial designs that enroll participants based on their genetics represent a potentially disruptive change that could improve patient outcomes, reduce costs associated with drug development, and further realize the goals of precision medicine. On March 8, 2017, the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health of the National Academies of Sciences, Engineering, and Medicine hosted the workshop Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development. Participants examined successes, challenges, and possible best practices for effectively using genetic information in the design and implementation of clinical trials to support the development of precision medicines, including exploring the potential advantages and disadvantages of such trials across a variety of disease areas. This publication summarizes the presentations and discussions from the workshop.
| Author | : Thomas J. Dougherty |
| Publisher | : CRC Press |
| Total Pages | : 260 |
| Release | : 2003-05-14 |
| Genre | : Medical |
| ISBN | : 0203911466 |
Exploring innovative routes of drug discovery in the postgenomic era, Microbial Genomics and Drug Discovery examines bioinformatic and genomic approaches for the identification, detection, selection, and validation of new antibacterial targets and vaccine candidates. The book discusses potential pathways for effective infection control, inhibition of antibacterial resistance, and acceleration of the drug discovery process. This comprehensive reference describes procedures to recognize common targets in various bacterial species for the design of broad-spectrum antibiotics and clearly illustrates the use of pathway tools in a genomics-based drug discovery project.
| Author | : |
| Publisher | : |
| Total Pages | : 109 |
| Release | : 2012 |
| Genre | : Drugs |
| ISBN | : 9780309260213 |
The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description
| Author | : |
| Publisher | : Elsevier |
| Total Pages | : 429 |
| Release | : 2011-07-29 |
| Genre | : Science |
| ISBN | : 0080471013 |
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume stands as the first ever thematic volume in the series, focusing on the topic of genomics in cancer drug development. The chapters included in this book represent the cutting-edge information in the field and span such topics as Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics; Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches; The Application of siRNA Technology to Cancer Biology Discovery; Ribozyme Technology for Cancer Gene Target Identification and Validation; Cancer Cell-Based Genomic and Small Molecule Screens; Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer Models in Drug Discovery; Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development – Quantification of Emerging Protein Biomarkers; Molecular Optical Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in the United States, Europe and Japan.
